12,372 trials
Kidney, Polycystic
Primary: Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death. — 116; 115…
Chronic Kidney Disease
Primary: Number of Participants With Contrast-induced Acute Kidney Injury — 146; 146 participants
Bipolar Disorder
Primary: Number of Participants Who Experienced Clinical or Laboratory Adverse Events — 197; 74 Participants
Purpura, Thrombocytopenic, Idiopathic and Hepatitis C
Primary: Number of Participants (Responders) Achieving a Platelet Count >=50×10^9/L After the First 6 Weeks of Stage 1 — 3; 60 Participants — p=<0.001
Genital Warts · Anal Cancer · Anal Intraepithelial Neoplasia
Primary: Geometric Mean Titers (GMTs) to the HPV Types Contained in the 9vHPV Vaccine — 782.0; 703.9; 568.9; 616.7 milli Merck Units/mL — p=<0.001
Skin Diseases · Infectious
Primary: Change of Erythrocyte Volume Fraction(Percentage of Erythrocyte Volume in Total Volume of Blood) — 0.00; 0.01 percentage
Prevent Bleeding in Major Surgery
Primary: Overall Hemostatic Efficacy (Success or Failure) of Wilate, Based on the Intra-operative Assessment of the Surgeon and the Post-operative Assessment by the Investigator…
Hypoparathyroidism
Primary: The Percentage of Subjects Who Met the Triple Efficacy Endpoint Criteria at Week 24. — 2.5; 54.8 percentage of participants — p=<0.001
Hypoparathyroidism
Primary: Percentage of Subjects Who Achieved the Primary Triple Endpoint at Week 8, Based on Investigator Prescribed Data. — 21.1; 26.1 percentage of participants — p=>0.999
Opioid Dependence
Primary: Change of Opioid Use From Week 1 to 13 — 0.00; 0.27; 0.39 Mean Proportion of Opioid Use in Week 13 — p==0.00874
Meningococcal Disease
Primary: Percentage of Subjects With Serum Bactericidal Antibody (SBA) Titers ≥1:4 Against Neisseria Meningitidis Serogroup B by Vaccine Group. — 26; 24; 98; 27 percentage of…
Hypoparathyroidism
Primary: Percentage of Subjects Who Achieved the Primary Triple Endpoint at Week 24, Based on Investigator Prescribed Data. — 75.0 percentage of participants
Meningococcal Disease · Meningococcal Meningitis
Primary: Number of Subjects Reporting Unsolicited Adverse Events, Following Vaccination With Two Injections of rMenB+OMV NZ Vaccine Between Day 1 Through Day 91. — 2; 0; 0; 0…
Allergic Rhinoconjunctivitis
Primary: Frequency of Subjects With Adverse Drug Reactions — 133 participants
Polycythemia Vera
Primary: The Percentage of Participants Achieving a Primary Response at Week 32 — 22.7; 0.9 percentage of participants — p=< 0.0001